Michelson Diagnostics targets US market for skin cancer imaging
5 August 2011
Michelson Diagnostics has announced plans to expand availability of
revolutionary products for skin cancer imaging in the United
States with the formation of a US subsidiary.
The company has recruited Karen Miller
Gillis as VP Sales & Marketing / General Manager of its new US
subsidiary Michelson Diagnostics Inc., which is based
in Massachusetts. She brings 16 years’ sales and marketing
experience in the medtech industry.
“Karen’s background in sales and marketing of pay-per-use
billing will be hugely useful as we roll out our commercial
expansion in the USA”, said Michelson Diagnostics Ltd CEO Jon
Holmes. “Her commitment, drive and expert communication skills
were evident as soon as I met her, and I look forward to working
with Karen in this exciting period for the company.” he added.
“We believe that Michelson Diagnostics’ product, the
VivoSight OCT scanner, will provide dermatologists with new and
very useful information about what is happening below the
surface of the skin of their patients who are receiving
treatment for non-melanoma skin cancer.” said Karen. “Patients
who suffer from non-melanoma skin cancer will also benefit from
the non-invasive scan which allows their dermatologist to check
at prescribed intervals to ensure that treatment is progressing
as expected, and in some cases potentially avoid the biopsy
procedure and related waiting time.”
The VivoSight OCT scanner has received FDA clearance for
clinical use in the United States, and is currently being
trialed by leading skin cancer specialists at their clinics.
Source: Michelson Diagnostics